Shares of medical-device maker Cyberonics Inc. tumbled in Thursday morning trading after an analyst said past stock options granted to executives showed "unusual activity." SunTrust Robinson Humphrey analyst Amit Hazan said in a note he analyzed all the companies he covers and found that Cyberonics granted options to three executives, including Chief Executive Skip Cummins, on June 15, 2004, while the stock was halted just after a Food and Drug Administration panel recommended approval of the company's pacemaker-like medical device, VNS Therapy, to treat major depression.
The Houston Chronicle
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Procleix’s Zika Assay Earns FDA Approval for Use With Panther System
The assay is also approved to test plasma or serum samples to screen other living or dead organ donors and human cells, tissues and cellular and tissue-based products.
FDA Plans Study of Risk Information in Direct-to-Consumer Print Ads
The in-person study will consist of an hour-long 40-person pilot study, in addition to two hour-long studies with 200 voluntary participants each.
FDAnews Device Daily Bulletin
CYBERONICS DOWNGRADED ON STOCK OPTIONS
June 9, 2006